Exploring Longevity Research Through Data Science at Tokyo Science University
On May 15, 2025, at Tokyo Science University, the 'Longevity Research Seminar' was held, showcasing the latest advancements in health care and medicine through innovative data-driven approaches. This event, organized by the Medical Innovation Institute at the university, focused on enhancing healthcare with real-world data (RWD). Various enterprises and research institutions presented their cutting-edge initiatives aimed at improving health care and medical practices globally.
The seminar featured prominent organizations discussing the potential of RWD in transforming health care approaches. A special highlight was the presentation from Regenesome Inc., a subsidiary of Space Seed Holdings. The company specializes in applying data science techniques to explore critical issues surrounding aging, including the decline in quality of life (QOL) and the rising costs of social security as the population ages. Representatives from Regenesome, CEO Kengo Suzuki and President Yoshitaro Sakuma, shared insights on how they utilize data science to tackle these issues through various projects, which are as follows:
1. Analysis of Trends in Cognitive Dysfunction: By leveraging medical insurance and health check data, Regenesome aims to dissect trends associated with the onset of cognitive functional disabilities across age demographics. This analysis seeks to better understand the factors that contribute to cognitive decline with age.
2. Development of a Gene Therapy and AI Database: Plans were unveiled for constructing a comprehensive database centered around aging-related data, paving the way for innovative gene therapy solutions and artificial intelligence applications in the medical field.
3. Creation of New Health Care Products: Researchers are exploring the use of fermentation technology to develop unique health care products designed to promote the well-being of the elderly and enhance longevity.
4. Personal Aging Care Proposals: Regenesome also introduced easy-to-implement aging care strategies for individuals, thereby empowering people to take charge of their health and longevity through practical methods.
During the latter portion of the seminar, various cross-disciplinary research projects conducted within the dental and medical fields at Tokyo Science University were showcased. This segment illustrated specific cases of industry-academia collaboration that demonstrated the breadth of medical innovation stemming from partnerships between the university and leading companies.
Post-seminar, a networking session encouraged lively exchanges among attendees, fostering collaboration and knowledge sharing among the diverse participants. The evening ended with a casual gathering featuring showcased premium sake from Tsu and Koji Brewery.
Program Outline:
The Medical Innovation Institute at Tokyo Science University is a core organization dedicated to advancing medical practices and their implementation in society. It collaborates with researchers, businesses, and policymakers to promote the utilization of medical data, technology transfer, entrepreneurial support, and clinical development comprehensively. It seeks to realize evidence-based sustainable healthcare and medicine through its five specialized divisions collaborating closely.
Regenesome harnesses nanoparticles, including exosomes, to provide new solutions for aging suppression and regenerative medicine. Aiming to accelerate the development of both business and research, it plans to open the 'Takanawa Longevity Lab' in May 2025 within Takanawa Gateway Link Scholars’ Hub (LiSH). The company aspires to develop medical technologies and solutions within the field of space medicine, striving to enhance healthy lifespans while contributing to the human expansion into space.
For more details, visit Regenesome.
Space Seed Holdings operates as a deep-tech venture builder with the mission of turning science fiction into reality. Through investment initiatives and research activities complemented by participatory programs like the 'Fermentation and Longevity Fund,' they are focused on addressing social challenges through innovative solutions. They aim to equip humanity with the necessary technologies to inhabit space by 2040.
For media inquiries, contact Regenesome.
The seminar featured prominent organizations discussing the potential of RWD in transforming health care approaches. A special highlight was the presentation from Regenesome Inc., a subsidiary of Space Seed Holdings. The company specializes in applying data science techniques to explore critical issues surrounding aging, including the decline in quality of life (QOL) and the rising costs of social security as the population ages. Representatives from Regenesome, CEO Kengo Suzuki and President Yoshitaro Sakuma, shared insights on how they utilize data science to tackle these issues through various projects, which are as follows:
1. Analysis of Trends in Cognitive Dysfunction: By leveraging medical insurance and health check data, Regenesome aims to dissect trends associated with the onset of cognitive functional disabilities across age demographics. This analysis seeks to better understand the factors that contribute to cognitive decline with age.
2. Development of a Gene Therapy and AI Database: Plans were unveiled for constructing a comprehensive database centered around aging-related data, paving the way for innovative gene therapy solutions and artificial intelligence applications in the medical field.
3. Creation of New Health Care Products: Researchers are exploring the use of fermentation technology to develop unique health care products designed to promote the well-being of the elderly and enhance longevity.
4. Personal Aging Care Proposals: Regenesome also introduced easy-to-implement aging care strategies for individuals, thereby empowering people to take charge of their health and longevity through practical methods.
During the latter portion of the seminar, various cross-disciplinary research projects conducted within the dental and medical fields at Tokyo Science University were showcased. This segment illustrated specific cases of industry-academia collaboration that demonstrated the breadth of medical innovation stemming from partnerships between the university and leading companies.
Post-seminar, a networking session encouraged lively exchanges among attendees, fostering collaboration and knowledge sharing among the diverse participants. The evening ended with a casual gathering featuring showcased premium sake from Tsu and Koji Brewery.
Event Overview
- - Organizer: Tokyo Science University Medical Innovation Institute
- - Date: May 15, 2025
- - Time: 17:00 to 20:00
- - Location: Tokyo Science University, Yushima Campus, M&D Tower 26th Floor, Faculty Lounge
Program Outline:
- - 17:00 - Opening Remarks: Masahiro Matsuura, Special Appointed Professor
- - 17:10 - 'Utilization of Medical Data in Science Tokyo' by Asumi Ai
- - 17:20 - 'Examples of RWD Utilization and Co-Creation' by Taisuke Ichihara
- - 17:30 - 'Introduction to Longevity Research Utilizing Data Science' by Kengo Suzuki and Yoshitaro Sakuma
- - 17:55 - Importance of Integrating Dental and Medical Data presented by Risa Mikami
- - 18:10 - Building AI for Identifying Patients through Panoramic X-Rays presented by Takaki Sudo
- - 18:25 - Early Prediction of Pediatric Surgical Diseases from Big Data presented by Yoshifumi Itoh
- - 18:40 - Early Diagnosis of Atrial Fibrillation Using AI presented by Kentaro Takahashi
- - 19:00 - Closing Remarks
- - 19:00 - 20:00 Networking Session
About Tokyo Science University Medical Innovation Institute
The Medical Innovation Institute at Tokyo Science University is a core organization dedicated to advancing medical practices and their implementation in society. It collaborates with researchers, businesses, and policymakers to promote the utilization of medical data, technology transfer, entrepreneurial support, and clinical development comprehensively. It seeks to realize evidence-based sustainable healthcare and medicine through its five specialized divisions collaborating closely.
About Regenesome Inc.
Regenesome harnesses nanoparticles, including exosomes, to provide new solutions for aging suppression and regenerative medicine. Aiming to accelerate the development of both business and research, it plans to open the 'Takanawa Longevity Lab' in May 2025 within Takanawa Gateway Link Scholars’ Hub (LiSH). The company aspires to develop medical technologies and solutions within the field of space medicine, striving to enhance healthy lifespans while contributing to the human expansion into space.
For more details, visit Regenesome.
About Space Seed Holdings Inc.
Space Seed Holdings operates as a deep-tech venture builder with the mission of turning science fiction into reality. Through investment initiatives and research activities complemented by participatory programs like the 'Fermentation and Longevity Fund,' they are focused on addressing social challenges through innovative solutions. They aim to equip humanity with the necessary technologies to inhabit space by 2040.
For media inquiries, contact Regenesome.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.